Episurf Medical’s Episealer® Patellofemoral System under substantive review at the US FDA
Episurf Medical (NASDAQ: EPIS B) today announces that the company’s 510(k) application to the US FDA for market clearance for the Episealer® Patellofemoral System now is progressing to the substantive review phase. “This FDA notification is an important step in the process. We will continue our preparations for a US market launch while the application is undergoing the review” says Pål Ryfors, CEO Episurf Medical